<DOC>
	<DOCNO>NCT02134717</DOCNO>
	<brief_summary>The study hypothesize inhibition receptor CCR5 maraviroc diminish inflammation patient sarcoidosis . Subjects active sarcoidosis first undergo bronchoscopy bronchoalveolar lavage recover lung immune cell baseline analysis . They receive drug maraviroc 6 week duration . They undergo repeat bronchoscopy bronchoalveolar lavage recover lung immune cell analysis follow maraviroc treatment .</brief_summary>
	<brief_title>Impact CCR5 Inhibition Sarcoidosis Immunophenotypes</brief_title>
	<detailed_description>The investigator hypothesize inhibition CCR5 maraviroc may beneficial immunomodulatory effect granulomatous inflammation pulmonary sarcoidosis . The specific aim proposal investigate effect CCR5 inhibition traffic mononuclear cell lung , skin , peripheral blood subject active sarcoidosis expose CCR5 inhibitor , maraviroc . A second aim isolate cell sort CD4+CCR5+ T cell amplify gene expression profile CCR5 inhibition , experiment investigator believe elucidate gene associate downstream activation inhibition CCR5 receptor function .</detailed_description>
	<mesh_term>Sarcoidosis</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<criteria>1 . Histologically proven sarcoidosis site ( noncaseating granuloma without cause ) . 2 . Diagnosis active sarcoidosis ( Sec . 5.5.4.t ) clinical stage II CXR . 3 . FVC &gt; 4S % DLCO &gt; 50 % predicted value . 4 . Evidence active sarcoidosis ( see criterion ) 5 . Able willing complete study procedure ( e.g. , bronchoscopy , postdrug surveillance ) 6 . Age : 18+ year old ( prevalence great young adult ; pediatric maraviroc safety establish ) . 7 . Not immunosuppression sarcoidosis time recruitment , ( e.g. , steroid , TNFa blockade ) 8 . Liver function ( transaminase , bilirubin ) , coagulation ( INR , PTT , platelet count ) , BUN , creatinine , WBC within normal limit . 9 . If female : negative pregnancy test , agreement use reliable contraception childbearing potential 30 day prior 30 day study completion ( drug safety pregnancy establish ) . 10 . Negative HIV HBsAg test 1 . Diagnosis infection base upon clinical evaluation and/or microbial testing . 2 . The diagnosis disease involve heart , lung , liver ( HVC ) , kidney , hematologic , endocrine , Gl system , judgment PI , would pose undue risk subject participate study . This include limited diabetes , uncontrolled hypertension , liver disease ( HVC ) , history malignancy . 3 . Medications either inhibit induce CYP3A4 ( include St John 's Wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>sarcoidosis</keyword>
	<keyword>CCR5 inhibition</keyword>
	<keyword>maraviroc</keyword>
</DOC>